Philips defeats antitrust claims in ultrasound infringement suit
Philips was not anti-competitive when it refused a medical equipment maintenance company access to its software for ultrasound machines but did misuse its copyright, the US District Court for the Western District of Washington has ruled.
Indian court rejects AstraZeneca’s injunction request
The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Fed Circuit affirms GSK $107m patent loss
The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.
Medicure and Nexus agree Aggrastat generic licence
US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
Siemens sues ex-VP for stealing heart catheter trade secrets
A subsidiary of Siemens AG has accused a former vice president of stealing trade secrets related to heart catheter devices to assist his new employer, NuVera Medical, in developing a rival product.
Third Circuit under fire over FTC v AbbVie ruling
The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.
GSK, Amgen want SCOTUS to protect genus claims
Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.
Emer Cooke becomes first woman to lead EMA
The first woman to act as executive director of the European Medicines Agency (EMA) has officially started in the role.
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Generics sign patent pool pledge to improve access to COVID-19 treatments
In response to the surge of COVID-19 infections worldwide, 18 generic drug makers have pledged to join the effort by the Medicines Patent Pool to accelerate global access to effective COVID-19 treatments via a pool for voluntary product licences.
